TARS · Tarsus Pharmaceuticals, Inc.
$76.85
-1.77 (-2.25%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$3.32B
Shares
43.88M
Volume · Oct 1
166.74K
Avg daily vol (3M)
970.71K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$78.61
Open$76.76
Day$76.32–78.70
52W close$56.11–90.78
Avg vol 30d775K
Short int6.1M · 14.0% float · 6.6d
Short vol75%
Last earningsAug 6, 2026
DataOct 2020–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$606.33M
Trailing 12 months
Net income (TTM)
−$46.48M
Trailing 12 months
Revenue growth YoY
+69.4%
Year over year
Operating margin
-8.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
1.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$376.93M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.4%
Year over year · more shares
Price change (1Y)
+32.0%
Trailing year
Short interest
14.0%
Latest settlement · 6.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+15%
above
Price vs 50-day avg
+10%
above
RSI (14)
56
neutral
MACD trend
Negative
52-week position
65%
mid-range
Momentum
relative strength
1-month return
+6%
trailing
6-month return
+9%
trailing
YTD return
−4%
this year
Relative strength
−4%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $72 › 200d $69 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +40 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.96% of float · ▲ +1.9% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
258 holders — near 3-yr high, broad support
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
+147%
Y/Y
EPS growth
+48%
Y/Y
Free cash flow
$-22.3M
Balance sheet
$111.2M
net cash
Quant / Vol
risk profile
Volatility
46%
annualized · 1-yr
Max drawdown
−32%
past year
ATR
3.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
XDEMVY net product sales
· full-year 2026
Initiated
$685M – $705M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+15%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
56
Neutral
MACD trend
Negative
Bearish
52-week position
65%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $72 › 200d $69 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +40 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.96% of float · ▲ +1.9% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
258 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $56
Now $79 · 65%
Range high $91
vs 200-day avg +15%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TARS
this stock
Tarsus Pharmaceuticals, Inc.
|
$3.32B | -4.0% | +146.7% | — | 14.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TARS | +5.8% | +6.2% | +8.5% | +5.9% | -4.0% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +6.5% | +6.1% | -3.6% | +6.5% | -15.8% |